June 18, 2019
» Read More
This article was originally published in RealClearPolicy on June 14, 2019.
Millions of American patients benefit each year from thousands of life-saving drugs produced by drug manufacturers armed with powerful intellectual property (IP) protections for their products. If some in Congress had their way, however, basic patent protection could be labeled as “anti-competitive” activity, causing cutting-edge pharmaceutical innovation to go the way of the dodo. Sens. John Cornyn (R-Tex.) and Richard Blumenthal (D-Conn.) are on a mission to stop what they see as current-day “robber barons” who “crushed competition and stifled access to cheaper generic drugs” over the past few decades. Instead of destroying the IP protections undergirding countless game-changing medicines, lawmakers should work with producers to find ways to bring down costs and improve quality.
June 13, 2019
» Read More
This article was originally published on FEE.org on June 12, 2019.
Medicine has come a long way in 5,000 years of recorded history, but progress has hardly been even and neat. Health care and the public policy that shapes it are often more of a zig-zag toward progress than a straightly paved road. Case in point: The Trump administration has simultaneously proposed commendable rebate reform and disastrous price controls for pharmaceuticals. By rejecting price fixing and pursuing a consistently free-market approach, President Trump can ensure that America leads the way in innovative, life-saving therapies.
June 3, 2019
Like most half-baked, big government ideas, “Medicare for All” as proposed by Sen. Bernie Sanders (I-Vt.) sounds great on the surface. But as the citizens of countries with socialized medicine have come to learn, “free” medicine is never actually free. Patients regularly have to wait for many months to get life-saving treatments, while drugs to curb dangerous conditions such as high cholesterol are increasingly difficult to come by across Europe. That’s why rich nationals of these beleaguered countries flock to the US regularly to get treatment, even as the poor and working-class are condemned to substandard treatment. » Read More
May 28, 2019
This article originally appeared in the Catalyst on May 15, 2019.
To scholars studying the ins-and-outs of the U.S. healthcare system, the phrase “bending the cost curve” (lowering the cost growth of healthcare services) has become a mantra spread from one policy lunch to another. To millions of real Americans dealing with exorbitant medical bills, though, lowering medical costs is the single most important thing that policymakers can do to ease anxiety and improve quality of life. A recently-released study suggests that costs can in fact be lowered, but counterintuitively through higher-deductible healthcare plans. In other words, more skin in the game means lower costs for consumers and eventually taxpayers via lower federal health program costs. » Read More
May 6, 2019
» Read More
This article originally appeared in the Morning Consult on April 30, 2019.
Horror stories about the U.S. medical system are a dime-a-dozen, but few have attracted as much ire as “surprise billing.” When patients go to a hospital that is in their insurance network, they expect that payment will be a done deal. But sometimes, they receive an unexpected bill from a physician who accepts dissimilar insurance plans than those accepted by the hospital where the physician saw the patient.
April 30, 2019
WASHINGTON, D.C.– Today, the Food and Drug Administration (FDA) announced that it is allowing the selling of a revolutionary tobacco heating system known as IQOS. This reduced-risk product heats tobacco without burning it, allowing smokers the sensation of traditional smoking without releasing harmful carcinogens. Despite these benefits, the FDA took more than 2 years to approve the selling of this product. » Read More
April 30, 2019
» Read More
As insurance networks get narrower by the year thanks to the Affordable Care Act (ACA), the issue of “surprise billing”has policymakers in a bind. Every day, lawmakers and industry stakeholders hear stories of patients being treated at an in-network hospital yet still receiving $50,000 bills from out-of-network physicians operating from said hospitals. Too often, gaps and discrepancies in coverage leave patients with the sense that they may be slapped with extra costs for services and physicians they once assumed were within the scope of their coverage.
April 29, 2019
» Read More
Tomorrow (April 30), the House Energy and Commerce Committee will examine prescription drug payments in Medicare Parts B and D. Congress is to be applauded for looking into the rising cost of healthcare and it appears that the committee will discuss and examine recently proposed harmful practices such as step therapy. Instead of considering policies that will restrict care for patients, Congress should take a hard look at real cost drivers in our system, as well as the proposals to help lower costs for patients.
April 29, 2019
» Read More
This article originally appeared in InsideSources on April 25, 2019.
As many Americans have come to realize, the federal government rarely has the answers to America’s most pressing issues. But on the key issue of high (and rising) drug costs, the government – specifically the Department of Health and Human Services (HHS) – thinks that it can wave a magic wand and bring prices down in one fell swoop via an International Price Index (IPI). There are plenty of potential reforms that could increase the quality and decrease the cost of care, but IPI is a quack cure for America’s healthcare woes.
April 29, 2019
TPA joined together with free-market groups voicing strong support for the Trump Administration's efforts to eliminate drug rebate programs. While most actors in the drug pricing debates are held accountable, for too long PBMs have been able to remain unchallenged. President Trump is proposing to end this era of backdoor deals in the drug industry, bring real transparency to drug markets, and deliver savings directly to patients when they walk into the pharmacy. » Read More
April 11, 2019
This article originally appeared in the Catalyst on April 2, 2019.
For nearly a decade, the American public, insurers, and taxpayers have gotten used to hearing bad news about the Affordable Care Act (aka “Obamacare”) and have personally felt its effects. Premiums were rising, networks were narrowing, plans were being cancelled, and insurers were dropping out as then-President Obama assured the public that more Americans would soon be insured. But now, thanks in large part to Trump administration reforms, there’s finally a stable marketplace with falling prices. And now that the Department of Justice has announced it will no longer defend the law’s constitutionality, Obamacare’s final demise may not be far off. The administration and Congress have a historic opportunity to enact more market-oriented reforms that can cover more people at a lower cost to taxpayers and consumers. » Read More
April 1, 2019
This article was originally published in RealClearPolicy on April 1, 2019.
With enough research, development, and vision, a speculative “dream cure” for a terrible disease can turn into an obtainable reality for millions of patients. But unfortunately, sometimes government policy gets in the way of promising cures. In October 2018, the Department of Health and Human Services proposed a devastating rule that would tether Medicare Part B drugs to a rigid pricing structure modeled after European single-payer healthcare systems. » Read More
March 28, 2019
TPA joined together with free-market groups to explain why the proposed International Pricing Index (IPI) for Medicare Part B drugs will harm taxpayers and chill innovation. » Read More
March 26, 2019
This article was originally published in the Catalyst on March 23, 2019.
In 1971, President Richard Nixon declared war on an unconventional foe: cancer. Like the other war that was being waged at the time, policymakers had both some good but also many flawed ideas about how to beat the enemy. Thankfully, with the war on cancer, many of the good ideas won out and significant progress has been achieved in these past 48 years—owing primarily to the unleashing of market forces in developing game-changing cures. Now, as President Trump pledges to double down on cancer research funding, the chief executive, his administration, and Congress could stand to learn a thing or two about what has gone right—and wrong—during our nearly-fifty year tussle with this bitter and relentless foe. » Read More
March 18, 2019
» Read More
This article originally appeared in Morning Consult on March 18, 2019.
Thanks to cutting-edge investments in life-saving medicines, American companies continue to find cures for rare, devastating diseases. But America’s continued leadership in medical innovation depends on the federal government keeping sound, pro-innovation policies in place. Unfortunately, a growing group of lawmakers see drug pricing as arbitrary whims of greedy businessmen, rather than the price we pay for revolutionary research. Price-fixing proposals by members of Congressand bureaucrats would greatly restrict access to medications that Americans rely on every day and the potential for new, life-changing discoveries, creating unnecessary suffering from preventable diseases. Controls may bring prices down, but at an unacceptable cost.
March 7, 2019
Today, the Taxpayers Protection Alliance (TPA) along with fifteen additional free-market organizations sent a letter to Department of Health and Human Services Secretary Azar in support of transformative healthcare opportunities on the horizon, including cell and gene therapies. » Read More
February 27, 2019
This article originally appeared in Catalyst on February 25, 2019.
When a patient finds themselves in the back of an ambulance, there’s little question of the final destination. While emergency rooms (ERs) are ideal for potentially-fatal ailments such as heart attacks and gunshot wounds, the over-reliance on ERs for more minor issues diverts key dollars and personnel away from where they are needed. According to an IBM Watson study, nearly a quarter of patients in the ER didn’t, in fact, require medical attention, and more than 40 percent required care that could have been carried out in a primary care setting. » Read More
February 21, 2019
This article originally appeared in the Catalyst on February 15, 2019.
“Preventative medicine” is a great idea, except for the small caveat that the concept has saved few lives at a substantial cost. For example, according to researchers at the Harvard School of Public Health and Tufts–New England Medical Center, screening all 65-year-olds for diabetes (as opposed to screening only 65-year-olds with hypertension for diabetes) costs hundreds of thousands of dollars for each year of life saved. But what if a one-time shot early in life could prevent diseases such as diabetes altogether, saving countless lives and health care dollars? Fortunately, a new line of treatment—gene replacement therapy—offers the game-changing benefits to patients that doctors could only dream of a decade ago. And, this new technology could save taxpayers billions of dollars. » Read More
February 5, 2019
This article originally appeared in the Catalyst on January 31, 2019.
Anyone who has had a bacterial infection can attest to the misery of being bedridden and the frustration of taking medications that sometimes do not work. Why some drugs work and some don’t has been a mystery since the advent of modern medicine a century ago, but new advances in medical research show strong links between genetic variation and drug responses. » Read More
January 14, 2019
» Read More
This article originally appeared in the Catalyst on January 3, 2018.
The results are in, argues The Center for Public Integrity’s Wendell Potter: America’s healthcare system underperforms due to “the belief that the free market…can work as well in health care as it can in other sectors of the economy.” Don’t tell that to the more than 2 million Native Americans who receive their medical care through a federal service known as the Indian Health Service (IHS).